Merck KGaA (OTCMKTS:MKGAF – Get Free Report) is anticipated to announce its results before the market opens on Thursday, November 12th. Analysts expect Merck KGaA to post earnings of $2.47 per share and revenue of $6.20 billion for the quarter.
Merck KGaA Stock Performance
Shares of MKGAF stock opened at $170.10 on Tuesday. Merck KGaA has a 1-year low of $116.68 and a 1-year high of $175.56. The company has a current ratio of 1.31, a quick ratio of 0.84 and a debt-to-equity ratio of 0.27. The company has a market capitalization of $21.98 billion, a price-to-earnings ratio of 25.97 and a beta of 0.96. The stock’s fifty day simple moving average is $160.82 and its 200-day simple moving average is $152.03.
Merck KGaA Company Profile
Merck KGaA is a science and technology company headquartered in Darmstadt, Germany. Founded in 1668, it is distinct from the U.S.-based Merck & Co and operates internationally across healthcare, life science and electronics.
Its Healthcare business develops prescription medicines, including treatments in areas such as oncology, neurology, immunology and fertility. The Life Science business supplies products and services used in research, biotechnology and pharmaceutical manufacturing, including laboratory materials, equipment and solutions for bioprocessing.
Through its Electronics business, Merck provides specialty materials and technologies used in semiconductor and display manufacturing.
Featured Stories
- Five stocks we like better than Merck KGaA
- Wall Street May Be Making a Big Mistake With monday.com Stock
- Are These 2 Mid-Cap Growth Stocks Worth the Risk?
- Oklo Changes the Narrative: Does a Nuclear Stock Price Explosion Come Next?
- Cloudflare’s 20% Sell-Off May Have Created an Opening for Investors
Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.
